CCHMC

Silver Sponsor Molecular Devices at Society for Laboratory Automation and Screening 2023 International Conference and Exhibition

Retrieved on: 
Wednesday, February 22, 2023
Society, Organoid, Molecular Devices, Brain, Immortalised cell line, HUB, Magnetic 3D bioprinting, Biology, Workflow, Custom, Drug development, Automation, Acquisition, Software, Society for Laboratory Automation and Screening, Biomedical Research, CCHMC, Cincinnati Children's Hospital Medical Center, Poster, Cell, Laboratory automation, BAB, Good Samaritan Hospital Medical Center (West Islip, New York), SLAS, SAN, Exhibition, International Conference on Bioinformatics, Drug discovery, Conference, Pancreatic cancer, 3D, Mobile phone, Fine chemical, Medical imaging, Medical device, Research

SAN JOSE, Calif., Feb. 22, 2023 /PRNewswire-PRWeb/ -- Molecular Devices, LLC., a leading provider of high-performance life science solutions, is demonstrating its latest automated, high-throughput technology at this year's Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition from February 25 – March 1, 2023, in San Diego, Calif.

Key Points: 
  • Through a strategic acquisition and industry collaborations, Molecular Devices is demystifying the process of creating high-volume, viable, and reproducible organoids for drug discovery.
  • When complemented by Molecular Devices' high-performance, automated hardware and software solutions, the offering is a first-of-its-kind, turnkey solution for organoid development, screening, and analysis.
  • Novel analysis of neural outgrowth in 3D reconstructed human brain micro-tissues with application in compound screening on Tuesday, February 28, 2023: Poster by Molecular Devices.
  • For an overview of where to find Molecular Devices at SLAS 2023, visit the company's webpage here .

Vaica to announce a collaboration with the Children's Hospital of Michigan Foundation (CHM) as the technology partner for a new clinical trial.

Retrieved on: 
Tuesday, November 29, 2022
RPM, RTM, Communication, Medicine, Hospital, TEL, CCHMC, Telehealth, DRS, Health, Riley Children's Foundation, Children's Hospital of Michigan, Medical device, Child

The goal is to implement a new and effective digital clinical care workflow to improve patient outcomes.

Key Points: 
  • The goal is to implement a new and effective digital clinical care workflow to improve patient outcomes.
  • Target population include pediatric heart transplant recipients at Children's Hospital of Michigan.
  • The monitored medications including immunosuppressants are essential in the post-transplant regimen and are crucial to prevent post-transplant graft loss.
  • Established in 2003, Children's Hospital of Michigan Foundation is a Children's Foundation initiative dedicated to advancing the health and wellness of the children of Michigan.

Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins

Retrieved on: 
Friday, September 2, 2022
CEO, Technology, Safety, Strategic planning, Research, Negotiation, CURE, Cincinnati, U.S. Securities and Exchange Commission, GLOBE, Board of directors, Company, Twitter, Association, Patient, CVS, Consumer, Time, Sale, Board, SEC, CFO, FDA, Communication, SG, HSCT, Industry, Security (finance), Advertising, OTC, Target Corporation, Cincinnati Children's Hospital Medical Center, Patent, Acceleration, Beauty, Instagram, Private Securities Litigation Reform Act, Growth, Marketing, Vitamin D, Stock, CCHMC, Audit committee, CPG, Founder CEO, Conference, Mental health, Annual report, Amazon (company), Forward-looking statement, 3D printing, Management, Pharmaceutical industry, Facebook, Walmart

OXNARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary broad platform and wellness technology company, today announced results for the quarter ended June 30, 2022.

Key Points: 
  • OXNARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (CURE), a proprietary broad platform and wellness technology company, today announced results for the quarter ended June 30, 2022.
  • Gross margins increased and we expect the high margin sales to accelerate with our new marketing initiatives.
  • In addition, CURE intends to monetize the patents through the commercialization of the technology or through the licensing or sale of the technology.
  • For further details please visit CUREs website under SEC filings to review its 10-Q filed September 2, 2022: www.curepharmaceutical.com/investors/sec-filings/
    About CURE Pharmaceutical Holding Corp.

Blue Water Vaccines Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Thursday, August 11, 2022
FDA, U.S. Securities and Exchange Commission, Securities Act of 1933, Risk, University, BWV, VLP, GLOBE, Private Securities Litigation Reform Act, SEC, Sale, Nov, Security (finance), Research, Government, OH, CCHMC, Cincinnati Children's Hospital Medical Center, Media, COVID-19, Company, Norovirus, Infection, Vaccine, Streptococcus pneumoniae, Malaria, S&P, Water, AOM, Nasdaq

CINCINNATI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (BWV or Blue Water Vaccines or the Company), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the closing of its previously announced private placement of 3,683,280 shares of common stock (or common stock equivalents in lieu thereof) to several healthcare-focused institutional investors, that was priced at-the-market under Nasdaq rules.

Key Points: 
  • CINCINNATI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (BWV or Blue Water Vaccines or the Company), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the closing of its previously announced private placement of 3,683,280 shares of common stock (or common stock equivalents in lieu thereof) to several healthcare-focused institutional investors, that was priced at-the-market under Nasdaq rules.
  • The gross proceeds from the private placement were approximately $10 million, before deducting placement agent fees and other offering expenses.
  • The Companys current cash position including the gross proceeds from this private placement is approximately $30.3 million.
  • Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally.

Blue Water Vaccines to Present at the JMP Securities Life Science Conference

Retrieved on: 
Monday, June 6, 2022
AOM, Interest, CCHMC, Research, Nov, Security (finance), Government, U.S. Securities and Exchange Commission, Malaria, University, Cincinnati Children's Hospital Medical Center, Vaccine, VLP, FDA, Private Securities Litigation Reform Act, OH, Infection, Streptococcus pneumoniae, COVID-19, Risk, BWV, St. Jude Children's Research Hospital, SEC, S&P, Hospital, Media, Norovirus, Pharmaceutical industry

BWVs management will be available during the conference for one-on-one meetings.

Key Points: 
  • BWVs management will be available during the conference for one-on-one meetings.
  • Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally.
  • Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.
  • Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford

Retrieved on: 
Tuesday, May 31, 2022
OH, Disease, Hospital, Private Securities Litigation Reform Act, VLP, U.S. Securities and Exchange Commission, Media, World, Oxford University Innovation, St. Jude Children's Research Hospital, Infection, World Health Organization, University, Vaccine, Government, Solution, Norovirus, Cincinnati Children's Hospital Medical Center, USD, Time, Â, AOM, COVID-19, CCHMC, Research, United Kingdom, FDA, H3, Water, Nov, Partnership, WHO, Absenteeism, QS, BWV, S&P, University of Oxford, Risk, CDC, Epitope, Streptococcus pneumoniae, SEC, Malaria, Hepatitis B vaccine, Security (finance), Influenza, GLOBE, Pharmaceutical industry

Under this amendment, BWV will extend funding for research into its universal influenza vaccine candidate, BWV-101, for an additional 18 months.

Key Points: 
  • Under this amendment, BWV will extend funding for research into its universal influenza vaccine candidate, BWV-101, for an additional 18 months.
  • The signing of this amendment, as well as additional funding provided by BWV, will enable Oxford to continue research and optimization of the Companys universal influenza vaccine candidate, BWV-101.
  • We are thrilled to continue our partnership with The University of Oxford, said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines.
  • This work brings us one step closer to a truly universal influenza vaccine, and we look forward to reaching that milestone with our partners at Oxford.

Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate

Retrieved on: 
Thursday, May 19, 2022
University, OH, Hospital, FAPESP, Private Securities Litigation Reform Act, VLP, Public health, Overalls, U.S. Securities and Exchange Commission, Media, First Nations in Ontario, World, St. Jude Children's Research Hospital, Infection, World Health Organization, Vaccine, Government, Norovirus, Cincinnati Children's Hospital Medical Center, COVID-19, AOM, Pan American Health Organization, Research, CCHMC, FDA, Institute, Water, Nov, Partnership, Center, São Paulo Research Foundation, BWV, S&P, Risk, Security (finance), Epitope, Immune system, Streptococcus pneumoniae, SEC, Malaria, Escherichia coli, United Nations, Instituto Butantan, CEO, Achievement, UNICEF, GLOBE, Pharmaceutical industry, Health

CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. (BWV or Blue Water Vaccines or the Company) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in Immunobiologics (CeRDI), an initiative of Instituto Butantan (Butantan).

Key Points: 
  • CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. (BWV or Blue Water Vaccines or the Company) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in Immunobiologics (CeRDI), an initiative of Instituto Butantan (Butantan).
  • Through this partnership, Butantan, a leading Brazilian producer of immunobiologic products and vaccines, and BWV will develop the universal influenza vaccine candidate, BWV-101, in Brazil.
  • Instituto Butantan was approved for a grant from The State of Sao Paulo Research Foundation (FAPESP) to develop BWVs universal influenza vaccine candidate in Brazil.
  • Blue Water Vaccines is developing a universal influenza vaccine that could potentially provide lifelong protection from influenza, including pandemic strains like the 1918 pandemic and 2009 swine flu.

CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell

Retrieved on: 
Thursday, May 12, 2022
Patient, Parent, Vitamin D, Compliance, CCHMC, Medical device, Dietary supplement

The median vitamin D level at baseline was 29.4 ng/mL, significantly improved (p Median vitamin D level at baseline was 29.4 ng/mL, significantly improved (p 0.0001) to 5.5ng/mL at the end of the study).

Key Points: 
  • The median vitamin D level at baseline was 29.4 ng/mL, significantly improved (p Median vitamin D level at baseline was 29.4 ng/mL, significantly improved (p 0.0001) to 5.5ng/mL at the end of the study).
  • Vitamin D is essential for bone health and has immunomodulatory properties.
  • Most pediatric patients are vitamin D insufficient (
  • Among CUREs key products is its oral thin film, 40,000 IU dose Vitamin D, (Branded Nutri-Strips in the Retail Market).

Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, May 12, 2022
OH, Hospital, Private Securities Litigation Reform Act, VLP, U.S. Securities and Exchange Commission, Media, St. Jude Children's Research Hospital, Infection, Vaccine, Government, Norovirus, Cincinnati Children's Hospital Medical Center, COVID-19, University, AOM, CCHMC, Research, FDA, Nov, Interest, BWV, S&P, Risk, Streptococcus pneumoniae, SEC, Malaria, Security (finance), Pharmaceutical industry

Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally.

Key Points: 
  • Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally.
  • Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.
  • Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.
  • There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.

Blue Water Vaccines Announces Expanded License Agreement with St. Jude Children’s Research Hospital for Novel Bacterial Vaccine Platform

Retrieved on: 
Wednesday, May 11, 2022
Child, COVID-19, Streptococcus pneumoniae, Private Securities Litigation Reform Act, Water, University, National Cancer Institute, Failure, OH, Malaria, GLOBE, CCHMC, Company, Cincinnati Children's Hospital Medical Center, NCI-designated Cancer Center, Social media, BWV, Pediatrics, Survival, Risk, FDA, St. Jude Children's Research Hospital, Hospital, American Academy of Pediatrics, AOM, Norovirus, Urinary tract infection, VLP, Government, Publication, NTNUI, Vaccine, Antigen, Public health, American Academy, Nov, Media, SEC, Infection, Research, S&P, Bacteria, USD, Pharmaceutical industry

CINCINNATI, May 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (BWV or Blue Water Vaccines or the Company), a biopharmaceutical company developing transformational vaccines, today announced an expanded license agreement has been signed with St. Jude Childrens Research Hospital (St. Jude).

Key Points: 
  • CINCINNATI, May 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (BWV or Blue Water Vaccines or the Company), a biopharmaceutical company developing transformational vaccines, today announced an expanded license agreement has been signed with St. Jude Childrens Research Hospital (St. Jude).
  • Through research funded by Blue Water Vaccines, St. Jude designed genetic constructs to express bacterial proteins on the surface of Streptococcus pneumoniae.
  • Through this expanded license agreement, we look forward to exploring the possibility of developing this preliminary research into a new vaccine platform and addressing public health unmet needs through efficacious vaccines, said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines.
  • Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally.